Mizuho upgraded Bloom Energy (NYSE: BE) to Outperform on Monday, citing strong risk/reward dynamics and growing demand for ...

Investing.com -- The Federal Trade Commission (FTC) and the Department of Justice Antitrust Division (DOJ) issued a joint directive today ordering the leaders of federal agencies to compile a list of ...

Everyone can see the bond market is throwing a tantrum: front-end yields have rapidly declined signaling nervousness about the state of the US economy, yet at the same time long-end yields are not ...

Despite continued headwinds in continental Europe, which Karp said “doesn’t quite get AI,” he stressed that 90% of Palantir’s ...

For the first quarter ended March 31, 2025, Zimmer Biomet reported net sales of $1.909 billion, marking a 1.1% increase from the previous year and a 2.3% rise on a constant currency basis. The company ...

Last Wednesday, the Quebec government announced that it would not be injecting any more public funds into Lion Electric. This decision led to the company laying off all but 12 of its employees.

Investing.com -- Palantir Technologies fell in afterhours trading Monday even as the data analytics company’s increased its full-year outlook following stronger-than-expected Q1 results. Palantir ...

Celanese implemented several actions during Q1 to drive earnings growth and increase cash generation in the current global environment. These included completing transactions to improve its debt ...

Investing.com -- Shell USA announced a change in its leadership, with Gretchen Watkins, who has served as President since July 1, 2018, set to step down on July 31, 2025. Watkins has held the position ...

This expansion is a strategic move to accelerate WeRide and Uber’s joint ambition of establishing autonomous mobility on a ...

HealthStream’s revenue growth was hampered by a $1.7 million reduction from attrition in legacy applications, a $0.9 million decrease in perpetual license sales, and a $0.6 million decline due to ...

The positive response to the news is attributed to the trial’s demonstration of a more than doubling in median OS compared to anti-PD-1 monotherapy, a standard treatment for this condition. The data, ...